Skip to content

Campare the effectiveness and safety of Olanzapine tablet and cariprazine tablet in patients of bipolar disorder.

A Comparative study to evaluate the efficacy and safety of Olanzapine and Cariprazine in patients with Bipolar disorder - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073456
Enrollment
72
Registered
2024-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F319- Bipolar disorder, unspecified

Interventions

Intervention1: Cariprazine: 1.5 mg OD for one month Control Intervention1: Olanzapine: 5 mg OD for one month

Sponsors

Dr Mukesh kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients or attendant giving written informed consent 2 Male and female patients who met diagnostic criteria for bipolar disorder and a major depressive episode as defined by DSM-IV 3 Patients will be required to have been in a depressive episode

Exclusion criteria

Exclusion criteria: 1 Patient not willing to participate in the study. 2 Unstable medical illness 3 History of diabetes 4 Recent substance dependence. 5 History of serious psychiatric illness other than bipolar disorder. •depot antipsychotics or central nervous system medications other than mood stabilisers •Current rapid-cycling mood disturbance

Design outcomes

Primary

MeasureTime frame
Quality of lifeTimepoint: Baseline, 2weeks, 4weeks,

Secondary

MeasureTime frame
Adverse drug reaction of drugsTimepoint: Every 2 weeks for 4 weeks.

Countries

India

Contacts

Public ContactDr Mukesh Kumar

Baba Raghav Das Medical college.Gorakhpur

dranilk194@gmail.com8303060884

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026